Notably, deletion of protein tyrosine phosphatase nonreceptor type 2 (PTPN2), a negative modulator of STAT1/JAK1 signaling, enhanced the efficiency of immunotherapy in melanoma tumors by increasing the activation of CD8+ T cells and the IFN-γ signaling pathway. Here, JAK1 is linked to melanoma.